Streetbeat News

Products Services

KROS

Keros Therapeutics presented additional data from its ongoing Phase 2 trial of KER-050 in patients with myelodysplastic syndromes and preclinical data showing KER-050 to restore erythropoiesis in myelofibrosis. The company also announced preclinical data evaluating ALK2 inhibition and its combination with KER-050 as potential treatment options for anemia of inflammation.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 10:03 am

AZN

AstraZeneca announced positive results from the Phase III ALPHA trial of danicopan as an add-on to Ultomiris or Soliris, showing a significant increase in haemoglobin levels and maintained disease control in patients with PNH experiencing EVH. The data was presented at the EHA Annual Meeting in Frankfurt.

Portfolio Pulse from Charles Gross

June 09, 2023 | 8:51 am

GM

TSLA

GM CEO Mary Barra returned to Twitter after a 7-month hiatus, hosting a Twitter Spaces session with Tesla CEO Elon Musk. During the session, GM and Tesla announced a collaboration allowing GM customers to access Tesla's supercharger network.

Portfolio Pulse from Anan Ashraf

June 09, 2023 | 8:15 am

EDIT

Editas Medicine announced positive initial safety and efficacy data from the first four patients with sickle cell disease treated with EDIT-301 in the RUBY trial and the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:30 am

KYMR

Kymera Therapeutics (NASDAQ:KYMR) will present preclinical data on KT-253, a potent and selective heterobifunctional MDM2 degrader, at the European Hematology Association Congress from June 8-15, 2023.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:29 am

IMGN

ImmunoGen Inc. announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine in patients with BPDCN. The data will be presented at the EHA 2023 Congress in Frankfurt, Germany.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:27 am

ABBV

GMAB

Genmab announced data from its phase 1/2 EPCORE™ NHL-2 trial, showcasing a 98% overall response rate and 87% complete metabolic response in patients with relapsed or refractory follicular lymphoma. The trial investigates epcoritamab in combination with rituximab-lenalidomide. Epcoritamab is co-developed by Genmab and AbbVie as part of their oncology collaboration.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:26 am

ABBV

AbbVie announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO/VENCLEXTA-based combination therapies in patients with previously untreated CLL with co-existing conditions, as well as R/R CLL. The results are being presented at the EHA Annual Congress in Frankfurt, Germany.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:25 am

BGNE

BeiGene presented new data from its blood cancer portfolio and early-stage pipeline products at the 2023 European Hematology Association (EHA) Hybrid Congress. The company has ten accepted abstracts at the event, which took place from June 8-11 in Frankfurt, Germany.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:23 am

CRSP

VRTX

Vertex Pharmaceuticals and CRISPR Therapeutics announced positive results from pivotal trials of exa-cel for transfusion-dependent beta thalassemia and severe sickle cell disease. Both trials met primary and key secondary endpoints at pre-specified interim analyses.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:21 am